Literature DB >> 10655060

LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

S Shackleton1, D J Lloyd, S N Jackson, R Evans, M F Niermeijer, B M Singh, H Schmidt, G Brabant, S Kumar, P N Durrington, S Gregory, S O'Rahilly, R C Trembath.   

Abstract

The lipodystrophies are a group of disorders characterized by the absence or reduction of subcutaneous adipose tissue. Partial lipodystrophy (PLD; MIM 151660) is an inherited condition in which a regional (trunk and limbs) loss of fat occurs during the peri-pubertal phase. Additionally, variable degrees of resistance to insulin action, together with a hyperlipidaemic state, may occur and simulate the metabolic features commonly associated with predisposition to atherosclerotic disease. The PLD locus has been mapped to chromosome 1q with no evidence of genetic heterogeneity. We, and others, have refined the location to a 5.3-cM interval between markers D1S305 and D1S1600 (refs 5, 6). Through a positional cloning approach we have identified five different missense mutations in LMNA among ten kindreds and three individuals with PLD. The protein product of LMNA is lamin A/C, which is a component of the nuclear envelope. Heterozygous mutations in LMNA have recently been identified in kindreds with the variant form of muscular dystrophy (MD) known as autosomal dominant Emery-Dreifuss MD (EDMD-AD; ref. 7) and dilated cardiomyopathy and conduction-system disease (CMD1A). As LMNA is ubiquitously expressed, the finding of site-specific amino acid substitutions in PLD, EDMD-AD and CMD1A reveals distinct functional domains of the lamin A/C protein required for the maintenance and integrity of different cell types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655060     DOI: 10.1038/72807

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  174 in total

Review 1.  The genetics of type 2 diabetes.

Authors:  M McCarthy; S Menzel
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 2.  Molecular mechanisms of adipocyte differentiation.

Authors:  Q Tong; G S Hotamisligil
Journal:  Rev Endocr Metab Disord       Date:  2001-10       Impact factor: 6.514

Review 3.  Many roads lead to a broken heart: the genetics of dilated cardiomyopathy.

Authors:  J Schönberger; C E Seidman
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

4.  Partial lipodystrophy, polycystic ovary syndrome and proteinuria: a common link to insulin resistance?

Authors:  V C Blackwell; P Salis; R W Groves; S E Baldeweg; G S Conway; R J Unwin
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

Review 5.  Lipoatrophic diabetes and other related syndromes.

Authors:  Elif Arioglu Oral
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 6.  Genetics of diabetes.

Authors:  Richard B Horenstein; Alan R Shuldiner
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

Review 7.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

Review 8.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

9.  New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.

Authors:  Angelika Lüdtke; Janine Buettner; Hartmut H-J Schmidt; Howard J Worman
Journal:  J Med Genet       Date:  2007-09       Impact factor: 6.318

10.  Lamin A N-terminal phosphorylation is associated with myoblast activation: impairment in Emery-Dreifuss muscular dystrophy.

Authors:  V Cenni; P Sabatelli; E Mattioli; S Marmiroli; C Capanni; A Ognibene; S Squarzoni; N M Maraldi; G Bonne; M Columbaro; L Merlini; G Lattanzi
Journal:  J Med Genet       Date:  2005-03       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.